- Company home
- Corporate objectives
- Company performance and financials
- Funding and venture capital
- Directors
Company latest
News and press
April 2009
Focus launches Citalopram Drop…
Focus has launched Citalopram Drops, a niche product on the generic market in the UK.…
Full storyPerformance and financials
Focus has since 2004 delivered a compound annual growth rate (“CAGR”) in sales and gross profit of 19%. In operating profit, the CAGR was 73%
Focus runs the business under a virtual model, outsourcing any areas that are considered “non-core”. This enables the business to concentrate on areas that add value to the business
The graph below shows the historical and expected growth of the business.
